Sentences with phrase «act as growth factors»

These SCFA are the prime substrates for the energy metabolism in the colonocyte and they act as growth factors to the healthy epithelium.

Patterson, one of the few scientists who began studying the role of immune molecules in neurons before Shatz, has long focused on cytokines, messenger molecules that regulate inflammation in the body and (as Patterson eventually discovered) act as growth factors in the developing brain.

These nutrients acted as growth factors which, in addition to the EPCs, allowed the resulting silk structure to support the formation of functioning platelets.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

Such risks, uncertainties and other factors include, without limitation: (1) the effect of economic conditions in the industries and markets in which United Technologies and Rockwell Collins operate in the U.S. and globally and any changes therein, including financial market conditions, fluctuations in commodity prices, interest rates and foreign currency exchange rates, levels of end market demand in construction and in both the commercial and defense segments of the aerospace industry, levels of air travel, financial condition of commercial airlines, the impact of weather conditions and natural disasters and the financial condition of our customers and suppliers; (2) challenges in the development, production, delivery, support, performance and realization of the anticipated benefits of advanced technologies and new products and services; (3) the scope, nature, impact or timing of acquisition and divestiture or restructuring activity, including the pending acquisition of Rockwell Collins, including among other things integration of acquired businesses into United Technologies» existing businesses and realization of synergies and opportunities for growth and innovation; (4) future timing and levels of indebtedness, including indebtedness expected to be incurred by United Technologies in connection with the pending Rockwell Collins acquisition, and capital spending and research and development spending, including in connection with the pending Rockwell Collins acquisition; (5) future availability of credit and factors that may affect such availability, including credit market conditions and our capital structure; (6) the timing and scope of future repurchases of United Technologies» common stock, which may be suspended at any time due to various factors, including market conditions and the level of other investing activities and uses of cash, including in connection with the proposed acquisition of Rockwell; (7) delays and disruption in delivery of materials and services from suppliers; (8) company and customer - directed cost reduction efforts and restructuring costs and savings and other consequences thereof; (9) new business and investment opportunities; (10) our ability to realize the intended benefits of organizational changes; (11) the anticipated benefits of diversification and balance of operations across product lines, regions and industries; (12) the outcome of legal proceedings, investigations and other contingencies; (13) pension plan assumptions and future contributions; (14) the impact of the negotiation of collective bargaining agreements and labor disputes; (15) the effect of changes in political conditions in the U.S. and other countries in which United Technologies and Rockwell Collins operate, including the effect of changes in U.S. trade policies or the U.K.'s pending withdrawal from the EU, on general market conditions, global trade policies and currency exchange rates in the near term and beyond; (16) the effect of changes in tax (including U.S. tax reform enacted on December 22, 2017, which is commonly referred to as the Tax Cuts and Jobs Act of 2017), environmental, regulatory (including among other things import / export) and other laws and regulations in the U.S. and other countries in which United Technologies and Rockwell Collins operate; (17) the ability of United Technologies and Rockwell Collins to receive the required regulatory approvals (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the merger) and to satisfy the other conditions to the closing of the pending acquisition on a timely basis or at all; (18) the occurrence of events that may give rise to a right of one or both of United Technologies or Rockwell Collins to terminate the merger agreement, including in circumstances that might require Rockwell Collins to pay a termination fee of $ 695 million to United Technologies or $ 50 million of expense reimbursement; (19) negative effects of the announcement or the completion of the merger on the market price of United Technologies» and / or Rockwell Collins» common stock and / or on their respective financial performance; (20) risks related to Rockwell Collins and United Technologies being restricted in their operation of their businesses while the merger agreement is in effect; (21) risks relating to the value of the United Technologies» shares to be issued in connection with the pending Rockwell acquisition, significant merger costs and / or unknown liabilities; (22) risks associated with third party contracts containing consent and / or other provisions that may be triggered by the Rockwell merger agreement; (23) risks associated with merger - related litigation or appraisal proceedings; and (24) the ability of United Technologies and Rockwell Collins, or the combined company, to retain and hire key personnel.

Similar to capsaicin, tumor necrosis factor is suspected to both induce and reduce cancer cell growth, and was shown to commit cells to survival when stimulating EGFR transactivation mechanisms, indicating that EGFR could act as a molecular switch determining the antiapoptotic effect of tumor necrosis factor (50).

The study revealed that growth factors — especially one known as growth differentiation factor 9 — coming from the eggs drove the feeding tube multiplication and growth process, acting directly upon the genetic machinery of the follicle cells surrounding the egg.

Since it is known that 13 different members of the fibroblast growth factor, or Fgf, family act as signaling proteins between the two different tissues — dental mesenchyme and oral epithelium — during murine tooth development, Javed and colleagues looked for changes in Fgf ligands in the mice lacking Sp7.

They focused towards this end on the vascular growth factor Angiopoietin - 2, which is produced by endothelial cells and does not just control angiogenesis, but acts as a key responsiveness factor for endothelial cells.

Now Grove and a colleague, reporting in todays Science, have found that Fibroblast Growth Factor 8 (FGF8), whose absence prevents limbs from growing normally, acts as a signal telling the neocortex which way is front.

Activated ERK1 / 2 modulates the functions of several transcription factors, protein kinases, protein phosphatases, cytoskeletal proteins, signaling molecules, apoptosis - related proteins, as well as other types of proteins [32], while activated AKT modulates the function of numerous substrates involved in the regulation of cell survival, cell cycle progression and cellular growth [33, 34], whereas JNK acts as pro-apoptotic as well as anti-apoptotic depending on the conditions [35].

Sp1 binds to the GC - rich sequence on the proximal region of p21waf1 / cip1 promoter and acts as a mediator for the induction of p21waf1 / cip1 gene caused by transforming growth factor β (TGF - β; ref.

Recently, skeletal muscle has been recognized as an endocrine tissue with the capacity to secrete cytokines and growth factors, known as myokines, which can act on distant tissues.

[17 - 28] Much evidence indicates that GHRH acts as an autocrine / paracrine growth factor in many human cancers [6, 23, 29 - 31] including that of the breast.

These systemic factors coordinate growth between developing tissues and act as relays to adjust body growth in response to environmental changes.

Transforming growth factor beta, TGFβ, acts as an anti-proliferative factor in epithelial cells.

It acts on liver and other tissues to stimulate the production of insulinlike growth factors (IGFs), including IGF - 1, which is also known as somatomedin C, and the production of IGF - binding proteins (IGFBPs), which also have direct cellular actions.

Lifting heavy weights, particularly deadlifts and squats work multiple muscle groups, requiring a ton of force exertion, which all act as triggers for your body to secrete the following hormones: testosterone, human growth hormone, and insulin like growth factor.

IGF - 1 also acts as a neurotrophic factor in the brain, contributing to neurogenesis (growth of new brain cells) and survival of existing neurons, along with better cognitive function.

Alabama has received a waiver from portions of the federal Elementary and Secondary Education Act (ESEA), which requires the state to include growth in student achievement as a significant factor in the evaluation framework, as well as a multitiered rating system.

The Illinois Performance Evaluation Reform Act (PERA), supported by both CPS and CTU, mandated that CPS install a comprehensive teacher evaluation system that is inclusive of both teacher practice and student growth as a «significant factor» by the fall of 2012 in at least 300 schools.

Implementation of favorable government regulations such as the Hydropower Regulatory Efficiency Act and Small Conduit Hydropower Development and Rural Jobs in the U.S. and growing number of funding programs pertaining to the renewable energy sector in developed countries such as Italy and Canada are some of the factors which are expected to present future growth opportunities.

However, other factors related to climate change — such as water scarcity or insect infestations — may act to stifle future forest fire activity by reducing growth or otherwise killing trees.

We expect that higher parenting quality at an early developmental stage acts as a growth - promoting factor.